Systemic anti-tumor combination medications
Phase 2
Systemic anti-tumor combination medications is one of 25 therapeutic programs targeting Non-small Cell Lung Cancer (NSCLC). It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
24
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
32 competitors in Non-Small Cell Lung Cancer (NSCLC)
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Trodelvy
GileadPhase 3
DATROWAY
Daiichi SankyoPhase 3
Alimta
EEagle Pharmaceuticals, Inc.
Phase 3
Paraplatin
AAvyxa
Phase 3
Sacituzumab Tirumotecan
Merck & Co.Phase 3
Xospata
AstellasPhase 1
Rina-S
GenmabPhase 2
Rasonque
Revolution MedicinesPhase 1
Gemcitabine/cisplatin
AstraZenecaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2[1]
- Company
- FFujian Cancer Hospital